| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.051 | 0.4 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |